Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
(S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide is an experimental small molecule inhibitor designed to target serine proteases, particularly trypsin-like serine protease 1 (PRSS1). It is a synthetic peptidomimetic compound containing a benzamidine moiety, which is known for its ability to inhibit serine proteases by mimicking the transition state of peptide substrates. The compound has been studied in structural biology as a selective inhibitor and probe for understanding the binding and inhibition of trypsin-like enzymes. Its primary mechanism involves competitive inhibition at the active site of these enzymes, preventing substrate cleavage[1][3][10]. There are no approved clinical indications or marketed formulations.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on (S)-N-(4-carbamimidoylbenzyl)-1-(3-cyclopentylpropanoyl)pyrrolidine-2-carboxamide.